Needham Initiates Kazia Therapeutics Coverage at Buy, Sets $27 Target
Needham initiated coverage of Kazia Therapeutics at Buy with a $27 price target. The target implies 209.6% upside from the Oct. 29 close of $8.72.
Related stories
ExxonMobil Q3 Revenue Rises 29.6% to $110.5 Billion, Below Estimates
ExxonMobil reported Q3 2026 revenue of $110.5 billion, up 29.6% year on year, and GAAP profit of $3.72 per share, 7% below analysts’ consensus estimates.
H impact | EQUITY | Oct 30, 2026, 01:45 PM UTC
General Dynamics Reports Q3 2026 Revenue of $14.57 Billion
Q3 revenue rose 12.9% year on year and exceeded Wall Street expectations. GAAP profit was $4.49 per share, 8.6% above analysts’ consensus.
H impact | EQUITY | Oct 30, 2026, 01:39 PM UTC
Microsoft Shares Hit 4-week Low
Microsoft shares decreased to 515.68 USD, the lowest since October 2026. Over the past 4 weeks, Microsoft gained 1.2%, and in the last 12 months, it decreased 1.27%.
L impact | EQUITY | Oct 30, 2026, 01:36 PM UTC
Exxon CEO Woods Expects Over $100 Billion in Capex Through 2030
M impact | EQUITY | Oct 30, 2026, 01:35 PM UTC
Church & Dwight Reports Q3 2026 Revenue of $1.60 Billion
Church & Dwight's Q3 2026 revenue rose 1% year over year to $1.60 billion, above Wall Street expectations. Its next-quarter revenue guidance of $1.64 billion was 1.4% below analyst
M impact | EQUITY | Oct 30, 2026, 01:35 PM UTC
Lockheed Martin Shares Hit 32-week High
Lockheed Martin shares increased to 650.03 USD, the highest since March 2026. Over the past 4 weeks, Lockheed Martin gained 27.24%, and in the last 12 months, it increased 32.32%.
L impact | EQUITY | Oct 30, 2026, 01:34 PM UTC